These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8945575)

  • 1. Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models.
    Van De Verg LL; Hartman AB; Bhattacharjee AK; Tall BD; Yuan L; Sasala K; Hadfield TL; Zollinger WD; Hoover DL; Warren RL
    Infect Immun; 1996 Dec; 64(12):5263-8. PubMed ID: 8945575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein.
    Bhattacharjee AK; Van de Verg L; Izadjoo MJ; Yuan L; Hadfield TL; Zollinger WD; Hoover DL
    Infect Immun; 2002 Jul; 70(7):3324-9. PubMed ID: 12065469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine.
    Bhattacharjee AK; Izadjoo MJ; Zollinger WD; Nikolich MP; Hoover DL
    Infect Immun; 2006 Oct; 74(10):5820-5. PubMed ID: 16988260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model.
    Bugybayeva D; Kydyrbayev Z; Zinina N; Assanzhanova N; Yespembetov B; Kozhamkulov Y; Zakarya K; Ryskeldinova S; Tabynov K
    Infect Dis Poverty; 2021 Feb; 10(1):13. PubMed ID: 33593447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice.
    Estein SM; Cassataro J; Vizcaíno N; Zygmunt MS; Cloeckaert A; Bowden RA
    Microbes Infect; 2003 Feb; 5(2):85-93. PubMed ID: 12650766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of intranasal and subcutaneous route of immunization in neonatal mice using DODAB-BF as adjuvant with outer membrane vesicles of Neisseria meningitis B.
    de Oliveira Santos FA; Lincopan N; De Gaspari E
    Immunobiology; 2018 Dec; 223(12):750-760. PubMed ID: 30055864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of immunopathophysiological responses induced by B. melitensis and its lipopolysaccharide in mouse model infected via intranasal route of exposure.
    Osman AY; Saharee AA; Jesse FF; Kadir AA
    Microb Pathog; 2017 Sep; 110():365-374. PubMed ID: 28710016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine.
    Donnelly JJ; Deck RR; Liu MA
    J Immunol; 1990 Nov; 145(9):3071-9. PubMed ID: 2120344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
    Opal SM; Palardy JE; Chen WH; Parejo NA; Bhattacharjee AK; Cross AS
    J Infect Dis; 2005 Dec; 192(12):2074-80. PubMed ID: 16288370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
    Orr N; Robin G; Cohen D; Arnon R; Lowell GH
    Infect Immun; 1993 Jun; 61(6):2390-5. PubMed ID: 8500877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rough brucella strain RM57 is attenuated and confers protection against Brucella melitensis.
    Feng Y; Peng X; Jiang H; Peng Y; Zhu L; Ding J
    Microb Pathog; 2017 Jun; 107():270-275. PubMed ID: 28390976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization.
    Abkar M; Lotfi AS; Amani J; Eskandari K; Ramandi MF; Salimian J; Brujeni GN; Alamian S; Kamali M; Koushki H
    Vet Res Commun; 2015 Dec; 39(4):217-28. PubMed ID: 26395469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic properties of Brucella melitensis cell-wall fractions in BALB/c mice.
    Cloeckaert A; Jacques I; Limet JN; Dubray G
    J Med Microbiol; 1995 Mar; 42(3):200-8. PubMed ID: 7884802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response.
    Steeghs L; Kuipers B; Hamstra HJ; Kersten G; van Alphen L; van der Ley P
    Infect Immun; 1999 Oct; 67(10):4988-93. PubMed ID: 10496868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization.
    Yang X; Walters N; Robison A; Trunkle T; Pascual DW
    Vaccine; 2007 Mar; 25(12):2261-8. PubMed ID: 17239499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance.
    Bakke H; Lie K; Haugen IL; Korsvold GE; Høiby EA; Naess LM; Holst J; Aaberge IS; Oftung F; Haneberg B
    Infect Immun; 2001 Aug; 69(8):5010-5. PubMed ID: 11447180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.
    Cassataro J; Estein SM; Pasquevich KA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH
    Infect Immun; 2005 Dec; 73(12):8079-88. PubMed ID: 16299302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immuno-pathophysiological responses of mouse model to experimental infection with Brucella melitensis and its lipopolysaccharides via intraperitoneal route.
    Osman AY; Abdullah FFJ; Kadir AA; Saharee AA
    Microb Pathog; 2016 Nov; 100():17-29. PubMed ID: 27591112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.
    Bhattacharjee AK; Opal SM; Taylor R; Naso R; Semenuk M; Zollinger WD; Moran EE; Young L; Hammack C; Sadoff JC; Cross AS
    J Infect Dis; 1996 May; 173(5):1157-63. PubMed ID: 8627067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design of new adjuvants for mucosal immunity to Neisseria meningitidis B in nasally primed neonatal mice for adult immune response.
    Ferreira T; De Gaspari E
    ScientificWorldJournal; 2012; 2012():292073. PubMed ID: 22545012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.